IBA President Umar Kremlev Joins Terence Crawford and Tyson Fury to Usher in Golden Era of International Boxing Association
7.7.2025 09:00:00 CEST | Business Wire | Press Release
Some of boxing’s biggest names gathered in Istanbul as International Boxing Association (IBA) President Umar Kremlev unveiled plans for the sport’s “Golden Era.” Joined by pound-for-pound star Terence Crawford and heavyweight icon Tyson Fury, Kremlev outlined IBA’s vision to build an ecosystem supporting fighters at every level- amateur, professional, and bare-knuckle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707636910/en/
IBA Press Conference (Photo: AETOSWire)
“I’m thrilled to welcome so many champions to this event for the development of boxing,” said Kremlev. “Our goal is to ensure every athlete knows IBA is their home. Wherever a boxer is, IBA will support them. It’s our duty to create opportunities for children to build better futures for themselves and their families.”
Kremlev stressed boxing’s roots: “We’re creating an ecosystem covering amateur, professional, and bare-knuckle boxing. Why bare-knuckle? That’s where it began. It’s boxing’s history. We want to regulate it and open chances for these fighters.”
The press conference took place before the WBA/IBA Pro title contest between Albert Batyrgaziev and James ‘Jazza’ Dickens, live on DAZN. IBA Pro, the association’s pro arm, matches top fighters in competitive bouts worldwide.
“The IBA has become an incredible home to express our vision,” said Al Siesta, Director of IBA Pro. “It’s like Real Madrid — you come through amateurs, earn your stripes, and when you want to go pro, we’ll look after you. We’re open to other governing bodies. This is collaboration, not competition. Rankings will be based on ability. If you can fight, IBA Pro is for you.”
Long known as an amateur boxing powerhouse, IBA now backs fighters with prize money and strong support to develop talent.
“President Umar Kremlev has done a sterling job,” said IBA Secretary General & CEO Chris Roberts OBE. “IBA is a hybrid platform managing kids from amateurs through to pros. The goal is to give them a path so they see heroes on TV and believe they can become champions.
“Our operational scale is huge. We’re here to deliver. We have the IBA Men’s World Boxing Championships this year in the UAE. The IBA Golden Era is something we’ve built over years. Umar has invested millions into federations that had nothing, all to support kids and future champions.”
Four-weight world champion Terence Crawford flew in before his fight with Saul ‘Canelo’ Alvarez to show support. “It’s great what IBA is doing for boxing. So many talented kids can’t afford to compete. IBA gives them a chance.” Crawford said, “I feel great, I’ve been working hard. I’m ready to become a three-weight undisputed champion this September.”
Tyson Fury praised IBA’s grassroots work. “Big shoutout to Umar Kremlev for bringing me here. Investment into amateurs is amazing. When I was an amateur, I didn’t get paid. Now, with Umar’s support, these youngsters have a real chance.”
Fury, who rose through AIBA (now IBA), teased a possible return. Asked about fighting Anthony Joshua for the IBA Pro Heavyweight title, he said: “Of course. 100%. Show me the money, Umar! I haven’t got an IBA Pro belt, but I’m young, free, single and ready to mingle!”
About the International Boxing Association:
The International Boxing Association (IBA) is the worldwide governing body of boxing, established in 1946. As the custodian of boxing, the IBA’s strategy is underpinned by an athlete-first approach, with a clear mission to promote, support, develop and unite prestigious and historic sport worldwide.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250707636910/en/
Contacts
Media contacts:
Elena Sobol, Head of Communications and PR, International Boxing Association:
elena.sobol@iba.sport
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom